Industry-corrupted psychiatric trials
نویسندگان
چکیده
منابع مشابه
Industry withdrawal from psychiatric medication development.
Between 1950 and 1969, on a serendipitous basis, psychiatric drug development flourished. However, there has been a steep decline in the development of new medication classes. Instead of new molecular entities, slight molecular modifications producing "me-too" drugs attempted to garner market share. With failing profitability, industry is now withdrawing from psychiatric medication development....
متن کاملDifferential Globalization of Industry- and Non-Industry–Sponsored Clinical Trials
BACKGROUND Mapping the international landscape of clinical trials may inform global health research governance, but no large-scale data are available. Industry or non-industry sponsorship may have a major influence in this mapping. We aimed to map the global landscape of industry- and non-industry-sponsored clinical trials and its evolution over time. METHODS We analyzed clinical trials initi...
متن کاملClinical trials and the pharmaceutical industry.
Authorization to market a drug is conditioned on submitting the results of clinical trials, proving that the product meets national and international standards and that it can be used to benefit human health. Who presents the proof? The manufacturer. Who authorizes use of the drug? The national regulatory agencies. Clinical trials are the epidemiological approach that provides the best evidence...
متن کاملGhost Authorship in Industry-Initiated Randomised Trials
BACKGROUND Ghost authorship, the failure to name, as an author, an individual who has made substantial contributions to an article, may result in lack of accountability. The prevalence and nature of ghost authorship in industry-initiated randomised trials is not known. METHODS AND FINDINGS We conducted a cohort study comparing protocols and corresponding publications for industry-initiated tr...
متن کاملPhase 0 trials: an industry perspective.
Worldwide, cancer is a leading cause of morbidity and mortality. An increased understanding of the disease and its process has resulted in a multitude of new targeted therapies. The costs as well as time from drug discovery to market, however, remain staggeringly high and protracted, with the majority of compounds never reaching phase III. The concept of an exploratory or phase 0 trial was intr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Psychiatria Polska
سال: 2017
ISSN: 0033-2674,2391-5854
DOI: 10.12740/pp/80136